Quarterly ResultApr 30, 2026, 08:17 AM
NCEL Secures $3.4M Financing; Accelerates NCEL-101 Diabetes Program
AI Summary
NewcelX Ltd. announced its financial results for the period ended December 31, 2025, alongside significant corporate highlights. The company secured up to $3.4 million in financing, including $1.35 million in cash and $2 million from warrants, and maintains access to a $25 million Equity Line of Credit, resulting in a substantially debt-free balance sheet. NewcelX is accelerating the development of its flagship Type 1 Diabetes program, NCEL-101, in collaboration with Eledon Pharmaceuticals, and strengthened its scientific leadership with a new Scientific Advisory Board appointment, aiming for accelerated execution in 2026.
Key Highlights
- Secured up to $3.4 million in financing, including $1.35 million cash and $2 million from warrants.
- Maintains access to a $25 million Equity Line of Credit.
- Balance sheet substantially debt-free as of December 31, 2025.
- Cash and cash equivalents were $2.2 million as of December 31, 2025.
- Net loss for 2025 was $8.3 million, including $5.7 million non-cash expenses.
- Net cash used in operating activities was $2.8 million in 2025.
- Appointed Julien Boisdron, MD, to Scientific Advisory Board to advance NCEL-101.
- Aims to significantly accelerate NCEL-101 development and clinical pipeline in 2026.
Price Impact
More from NCEL